Department of Food and Experimental Nutrition, Faculty of Pharmaceutical Sciences, University of São Paulo, Av. Lineu Prestes, 580, B14 - 05508-900, São Paulo, Brazil.
Dyslipidemia Medical Section, Dante Pazzanese Institute of Cardiology, Av. Dr. Dante Pazzanese, 500, 04012-909, São Paulo, Brazil.
Mol Metab. 2018 May;11:137-144. doi: 10.1016/j.molmet.2018.02.005. Epub 2018 Feb 20.
Statin intolerance, whether real or perceived, is a growing issue in clinical practice. Our aim was to evaluate the effects of reduced-dose statin therapy complemented with nutraceuticals.
First phase: Initially, 53 type 2 diabetic statin-treated patients received a supplementation with fish oil (1.7 g EPA + DHA/day), chocolate containing plant sterols (2.2 g/day), and green tea (two sachets/day) for 6 weeks. Second phase: "Good responders" to supplementation were identified after multivariate analysis (n = 10), and recruited for a pilot protocol of statin dose reduction. "Good responders" were then provided with supplementation for 12 weeks: standard statin therapy was kept during the first 6 weeks and reduced by 50% from weeks 6-12.
First phase: After 6 weeks of supplementation, plasma LDL-C (-13.7% ± 3.7, P = .002) and C-reactive protein (-35.5% ± 5.9, P = .03) were reduced. Analysis of lathosterol and campesterol in plasma suggested that intensity of LDL-C reduction was influenced by cholesterol absorption rate rather than its synthesis. Second phase: no difference was observed for plasma lipids, inflammation, cholesterol efflux capacity, or HDL particles after statin dose reduction when compared to standard therapy.
Although limited by the small sample size, our study demonstrates the potential for a new therapeutic approach combining lower statin dose and specific dietary compounds. Further studies should elucidate "good responders" profile as a tool for personalized medicine. This may be particularly helpful in the many patients with or at risk for CVD who cannot tolerate high dose statin therapy.
ClinicalTrials.gov, NCT02732223.
他汀类药物不耐受,无论是真实的还是被感知的,在临床实践中是一个日益严重的问题。我们的目的是评估减少剂量的他汀类药物治疗与营养补充剂相结合的效果。
第一阶段:最初,53 名接受他汀类药物治疗的 2 型糖尿病患者接受了为期 6 周的补充治疗,包括鱼油(1.7 g EPA+DHA/天)、含有植物固醇的巧克力(2.2 g/天)和绿茶(每天两袋)。第二阶段:通过多变量分析确定补充后的“良好反应者”(n=10),并招募他们参加一项他汀类药物剂量减少的试点方案。然后,“良好反应者”接受了 12 周的补充治疗:前 6 周继续使用标准他汀类药物治疗,第 6-12 周减少 50%。
第一阶段:补充治疗 6 周后,血浆 LDL-C(-13.7%±3.7,P=.002)和 C 反应蛋白(-35.5%±5.9,P=.03)降低。血浆中羊毛固醇和菜油固醇的分析表明,LDL-C 降低的强度受胆固醇吸收率而不是其合成的影响。第二阶段:与标准治疗相比,减少他汀类药物剂量后,血浆脂质、炎症、胆固醇外排能力或高密度脂蛋白颗粒没有差异。
尽管受到样本量小的限制,但我们的研究表明,联合使用低剂量他汀类药物和特定膳食化合物的新治疗方法具有潜力。进一步的研究应该阐明“良好反应者”的特征,作为个体化医学的工具。这对于许多不能耐受高剂量他汀类药物治疗的心血管疾病患者或有心血管疾病风险的患者可能特别有帮助。
ClinicalTrials.gov,NCT02732223。